应用小剂量阿斯匹林提高宫腔内授精妊娠率的临床观察

目的:本研究采用前瞻性随机双盲的方法,探讨小剂量阿斯匹林对提高宫腔内授精(IUI)妊娠率的临床效果。方法:采用CC/HMG/HCG方案促排卵,将行IUI的114例不孕妇女随机分为两组:观察组57例,于月经第1-20天连续服用阿斯匹林75mg/d;对照组57例,服用安慰剂。分别于排卵前1天和排卵后10天检测两组对象子宫动脉 血流阻力指数(RI)、子宫内膜形态、厚度及妊娠率。结果:两组妊娠率分别为24.6％和14％,子宫内膜呈三线征发生率分别为75.4％和50.8％,经比较均有显著性差异(P<0.01);与对照组比较,观察组RI显著降低(P<0.01),子宫内膜明显增厚(P<0.01)。结论:小剂量阿 斯匹林可改善子宫内膜发育,提高IUI妊娠率。     

阿司匹林对冠状动脉粥样硬化性心脏病血清C-反应蛋白水平的干预以及临床意义

目的探讨血清C反应蛋白(C-reactive protein,CRP)与不同临床类型冠状动脉粥样硬化性心脏病(Coronary Atherosclerotic Herat Disease,CAHD)的关系,以及阿司匹林对CRP水平的干预作用.方法前瞻性地对首次确诊的96例不同类型的CAHD与23例对照者抽取空腹静脉血,测定血清CRP;96例CAHD给予30d的阿司匹林肠溶片口服(每日100mg)后再次测量血清CRP.结果初诊患者与对照组相比,各组CAHD的CRP均有不同程度地升高,其中急性心肌梗死组与不稳定型心绞痛组升高最为显著(P＜0.05);口服30d阿司匹林肠溶片后,各组CAHD的CRP均有不同程度地降低,其中急性心肌梗死组与不稳定型心绞痛组降低最为显著(P＜0.05),但仍显著高于对照组.结论血清CRP与CAHD的发生、进展及不良事件的产生相关,口服阿司匹林可通过降低血清CRP,减少CAHD不良事件的发生.     

阿司匹林对人巨核细胞体外增殖的影响

目的:探讨阿司匹林对巨核细胞增殖、膜抗原表达及凋亡的影响.方法:将骨髓单个核细胞接种于含不同浓度阿司匹林的H2000培养基中,其中含Tpo 50ng·ml-1、SCF 50 ng·ml-1和IL-3 10ng·ml-1,5%CO2、37℃、饱和湿度的孵育箱中培养14d.结果:高浓度阿司匹林使巨核细胞的增殖变化明显高于低浓度,巨核细胞集落(CFU-MK)数减少,细胞丛(FFU-MK)数增加,CD41膜抗原表达率显著降低(P＜0.05);AnnexinV表达率明显增高(P＜0.05);DNA倍体分析的凋亡指数明显升高(P＜0.05);电镜观察可见出芽、空泡样结构和胞浆内颗粒减少.结论:高浓度阿司匹林可影响巨核细胞的正常代谢和促进其凋亡.     

Risk of bleeding after dentoalveolar surgery in patients taking anticoagulants

To avoid increasing the risk of thromboembolic events, it is recommended that treatment with anticoagulants should be continued during dentoalveolar operations. We have evaluated the incidence of bleeding after dentoalveolar operations in a prospective study of 206 patients, 103 who were, and 103 who were not, taking anticoagulants. Seventy-one were taking thrombocyte aggregation inhibitors and 32 vitamin K antagonists. Patients were treated according to guidelines developed at the Academic Centre for Dentistry Amsterdam (ACTA), The Netherlands. The operations studied included surgical extraction (when the surgeon had to incise the gingiva before extraction), non-surgical extraction, apicectomy, and placement of implants. Patients were given standard postoperative care and those taking vitamin K antagonists used tranexamic acid mouthwash postoperatively.     

高血压患者抗血小板治疗研究进展

心肌梗死和脑卒中是高血压最严重的并发症,且往往与血栓形成堵塞血管所致。抗血小板药物阿司匹林可以有效预防血栓性事件,因此抗血栓治疗可能减少这些并发症的发生。但抗血栓治疗是否应成为高血压患者的常规治疗措施,综述如下。     

Thrombolytic therapy-associated acute myocardial infarction in patients with acute ischemic stroke: A treatment dilemma

Acute myocardial infarction (AMI) is uncommon in the acute phase of acute ischemic stroke (AIS) and occurs in approximately 1% of the population. Here, we report a paradoxical case of AMI during tissue plasminogen activator (t-PA) infusion for AIS. We review and analyze the previously reported cases. We found that only patients with AMI which occurred after thrombolytic therapy for AIS who received an adequate combination of anticoagulation plus percutaneous coronary intervention survived their events. Several mechanisms have been proposed for the development of AMI after thrombolytic therapy. These mechanisms include fragmented intra-cardiac thrombus, intensified platelet aggregation that may lead to an increased potential for intra-cardiac thrombus formation, and a reduction in clot-associated plasminogen that may lead to a paradoxical hypercoagulable state of the coronary arteries. Currently, there is no consensus regarding this specific scenario. We propose that the therapeutic benefit and the potential risk of hemorrhagic complications should be further investigated and individualized. In patients who receive thrombolytic therapy for AIS and who then develop post-thrombolytic AMI, we suggest that the maximum treatment for the subsequent AMI be instituted promptly to avoid short-term mortality.     

PTGS1基因多态性与急性脑梗死患者阿司匹林抗血栓疗效的相关性

目的 探讨前列腺素内过氧化物合酶1(Prostaglandin-endoperoxide synthase1, PTGS1)基因多态性与急性脑梗死患者阿司匹林抗血栓疗效的相关性。方法 回顾性分析2017年10月-2020年10月在本院接受治疗的200例急性脑梗死患者的临床资料,按照其阿司匹林抗血栓疗效将其分为阿司匹林抵抗组(n=69)和阿司匹林敏感组(n=131),分析所有患者PTGS1基因多态性情况,比较2组性别、年龄、身体质量指数(Body Mass Index,BMI)、合并症(高血压病、冠心病、糖尿病)、PTGS1基因突变、不良嗜好(吸烟、酗酒)等临床特征及生化指标[血小板计数(Blood platelet,PLT)、超敏C反应蛋白(Hypersensitive-C reactive protein,hs-CRP)]水平,利用受试者工作特征(Receiver operating characteristic,ROC)曲线分析PLT,hs-CRP预测急性脑梗死患者阿司匹林抵抗的价值,将2组有差异的指标纳入Logistic回归分析模型,进行量化赋值,明确引起急性脑梗死患者阿司匹林抵抗的危险因素。结果 本研究200例急性脑梗死患者中PTGS1基因位点以AA为主,发生率为81.50%,其突变基因位点分别为AG,GG,占人数的14.00%、4.50%。阿司匹林抵抗组年龄≥60岁、合并糖尿病、PTGS1基因突变、吸烟患者的比例及PLT,hs-CRP水平显著高于阿司匹林敏感组(P<0.05)。经ROC曲线分析PLT,hs-CRP预测急性脑梗死患者阿司匹林抵抗的曲线下面积分别为0.879、0.866。年龄≥60岁、合并糖尿病、PTGS1基因突变、吸烟、PLT≥202.255×10⁹/L,hs-CRP≥24.695 mg/L是引起急性脑梗死患者阿司匹林抵抗的危险因素。结论 PTGS1基因多态性会增加急性脑梗死患者阿司匹林抵抗风险。除此之外,高龄、糖尿病、抽烟及PLT,hs-CRP异常高表达均可能影响阿司匹林抗血栓治疗效果。     

脑小血管病患者阿司匹林抵抗的发生率及其与长期预后的关系

【摘要】 目的 探讨脑小血管病（cerebral small vessel disease，CSVD）患者阿司匹林抵抗（aspirin resistance， AR）的发生率，以及AR与结局的关系。 方法 前瞻性纳入2015年8月-2017年6月诊断为CSVD的住院患者。根据血栓弹力图仪测量血小板 抑制率将患者分为AR组和非AR组。记录所有患者基线时人口学、实验室检查、影像学检查等资料，并 在2年随访期间进行影像学复查，同时记录患者新发血管事件及死亡情况。使用多因素Logistic回归分 析确定AR与结局的关系。 结果 共纳入94例患者，年龄为49～84岁，平均年龄66.20±7.37岁，男性55例（58.5%），AR的发生 率为23.4%（22/94）。AR与2年内新发腔隙性脑梗死（OR 4.70，95%CI 1.56～24.13，P =0.041）和脑白 质病变加重（OR 4.07，95%CI 1.28～11.57，P =0.038）风险相关，与新发血管事件及死亡风险无关。 结论 CSVD住院患者中AR发生率约1/5，AR与脑白质病变加重和新发腔隙性脑梗死风险相关。